Cellectar Biosciences Awarded Japanese Patent

Cellectar Biosciences said Tuesday it was granted a composition of matter patent by the Japanese Patent Office for the company’s optical imaging, phospholipid drug conjugates, CLR 1501 and CLR 1502.

The recently issued patent describes CLR 1501 and CLR 1502 for use in intraoperative tumor imaging both in vitro and in vivo. The patent allows intellectual property protection in Japan through May 11, 2030. Both compounds utilize the company’s PDC delivery platform for tumor targeting optimization. Shares of the clinical stage biopharmaceutical company were more than 1% higher at Tuesday’s open.

By Bucky Rini